Leap Therapeutics Valuation
| LPTX Stock | USD 0.42 0.01 2.44% |
Leap Therapeutics is overvalued. Leap Therapeutics secures a last-minute Real Value of $0.4 per share. The latest price of the firm is $0.42. Our model forecasts the value of Leap Therapeutics from analyzing the firm fundamentals such as Return On Equity of -1.07, current valuation of (46.55 M), and Shares Owned By Insiders of 3.40 % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Leap Therapeutics' price fluctuation is out of control at this time. Calculation of the real value of Leap Therapeutics is based on 3 months time horizon. Increasing Leap Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Leap Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Leap Stock. However, Leap Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.42 | Real 0.4 | Hype 0.42 | Naive 0.0571 |
The intrinsic value of Leap Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Leap Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Leap Therapeutics helps investors to forecast how Leap stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Leap Therapeutics more accurately as focusing exclusively on Leap Therapeutics' fundamentals will not take into account other important factors: Leap Therapeutics Total Value Analysis
Leap Therapeutics is now anticipated to have valuation of (46.55 M) with market capitalization of 15.9 M, debt of 262 K, and cash on hands of 90.88 M. The negative valuation of Leap Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Leap Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(46.55 M) | 15.9 M | 262 K | 90.88 M |
Leap Therapeutics Asset Utilization
One of the ways to look at asset utilization of Leap is to check how much profit was generated for every dollar of assets it reports. Leap Therapeutics secures a negative usage of assets of -0.58 %, losing $0.005805 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Leap Therapeutics shows how discouraging it operates for each dollar spent on its assets.Leap Therapeutics Ownership Allocation
Leap Therapeutics maintains a total of 38.32 Million outstanding shares. Over half of Leap Therapeutics' outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Leap Therapeutics Profitability Analysis
Net Loss for the year was (81.41 M) with profit before overhead, payroll, taxes, and interest of 1.5 M.About Leap Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Leap Therapeutics. We calculate exposure to Leap Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Leap Therapeutics's related companies.Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts. Leap Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 36 people.
Leap Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 20.4 M |
Additional Tools for Leap Stock Analysis
When running Leap Therapeutics' price analysis, check to measure Leap Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Leap Therapeutics is operating at the current time. Most of Leap Therapeutics' value examination focuses on studying past and present price action to predict the probability of Leap Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Leap Therapeutics' price. Additionally, you may evaluate how the addition of Leap Therapeutics to your portfolios can decrease your overall portfolio volatility.